



PATENT
Attorney Docket No.: UCSD1160-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gary S. Firestein et al.	Art Unit:	1633
Application No.:	10/716,647	Examiner:	A.M.S. Wehbe
Filing Date:	November 18, 2003	Conf. No.:	7684
Title:	THERAPY FOR CELLULAR ACCUMULATION IN CHRONIC INFLAMMATORY DISEASES		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, the references are listed on the attached Form PTO-1449.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
"EXPRESS MAIL" LABEL NUMBER <u>EM 023 788 820 US</u>	DATE OF DEPOSIT <u>June 27, 2007</u>
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.	
<u>Karen LePari</u> (TYPED OR PRINTED NAME OF PERSON MAILING PAPER)	<u>Karen LePari</u> (SIGNATURE OF PERSON MAILING PAPER OR FEE)

06/29/2007 FMETEK11 00000039 10716647

01 FC:1806

180.00 0P


In re Application of:
Gary S. Firestein et al.
Application No.: 10/716,647
Filed: November 18, 2003
Page 2

PATENT
Atty Docket No.: UCSD1160-4

Enclosed the fee required for the Information Disclosure Statements and for the claim amendments. No other fee is believed to be due in connection with filing this paper. However, the Commissioner is hereby authorized to charge any other fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A copy of the Transmittal sheet is enclosed.

Date: June 27, 2007

Respectfully submitted,



Daryl A. Basham, J.D., Ph.D.
Registration No. 45,869
Telephone: (858) 677-1429
Facsimile: (858) 677-1465

DLA PIPER US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer Number 28213



PATENT
Attorney Docket No.: UCSD1160-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Gary S. Firestein et al.	Art Unit:	1633
Application No.:	10/716,647	Examiner:	A.M.S. Wehbe
Filing Date:	November 18, 2003	Conf. No.:	7684
Title:	THERAPY FOR CELLULAR ACCUMULATION IN CHRONIC INFLAMMATORY DISEASES		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.97, Applicants bring to the Examiner's attention the related parent patent application, U.S. Serial No. 09/363,997 filed July 29, 1999, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
"EXPRESS MAIL" LABEL NUMBER <u>EM 023 788 820 US</u>	DATE OF DEPOSIT <u>June 27, 2007</u>
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.	
<u>Karen LePari</u> (TYPED OR PRINTED NAME OF PERSON MAILING PAPER)	<u>Karen LePari</u> (SIGNATURE OF PERSON MAILING PAPER OR FEE)

In re Application of:
Gary S. Firestein et al.
Application No.: 10/716,647
Filed: November 18, 2003
Page 2

PATENT
Atty Docket No.: UCSD1160-4


Applicants respectfully request that the references supplied in compliance with 37 C.F.R. § 1.97 in the above-referenced parent application, as well as those cited during its examination, be made of record. Copies of the documents will be found in the above-referenced parent application. For the convenience of the Examiner, enclosed are copies of Form PTO-1449 listing the reference cited by the Examiner or cited in an Information Disclosure Statement. Copies of the documents will be found in the above-referenced parent application.

It is respectfully requested that the parent application and the references cited therein be considered in the examination of this application and that their consideration be made of written record in the application file.

Enclosed the fee required for the Information Disclosure Statements and for the claim amendments. No other fee is believed to be due in connection with filing this paper. However, the Commissioner is hereby authorized to charge any other fees associated with the filing submitted herewith, or credit any overpayments to Deposit Account No. 07-1896 referencing the above-identified attorney docket number. A copy of the Transmittal sheet is enclosed.

Date: June 27, 2007

Respectfully submitted,




Daryl A. Basham, J.D., Ph.D.

Registration No. 45,869

Telephone: (858) 677-1429

Facsimile: (858) 677-1465

DLA PIPER US LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO Customer Number 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 	Docket No.: UCSD1160-4	Application No.: 10/716,647
	Applicants: Firestein et al.	Confirmation No.: 7684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 18, 2003	Group Art Unit: 1633

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		5,792,751	8/1998	Ledley et al.	514	44	
		6,069,134	5/2000	Roth et al.	514	44	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
		0 390 323 A2	10/03/1990	EP			
		WO 94/18992	09/01/1994	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

		Ledley F., "Pharmaceutical Approach to Somatic Gene Therapy." Pharmaceutical Res., Vol. 13: 1595-1613. 11/1996
		Eck et al., "Gene-based therapy." Goodman & Gilman's The Pharmacological Basis of Therapeutics-Ninth Edition." McGraw-Hill: 77-101. 1996
		Orkin et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy." Pages 1-20. 12/1995
		Miller et al., "Targeted vectors for gene therapy." FASEB Journal, Vol. 9: 190-199. 2/1995

EXAMINER GT6536670.1 328342-220	DATE CONSIDERED
--	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1160-4	Application No.: 10/716,647
	Applicants: Firestein et al.	Confirmation No.: 7684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 18, 2003	Group Art Unit: 1633

		Verma et al., "Gene therapy-promises, problems and prospects." Nature Vol. 389: 239-242. 09/97
		W. French Anderson, "Human gene therapy." Nature Vol. 392 Supp: 25-30 04/98
		Vaux et al., "The molecular biology of apoptosis." Proc. Natl. Acad. Sci. USA Vol. 93: 2239-2244 03/96
		Kumar et al., "Role of multiple cellular proteases in the execution of programmed cell death." FEBS Letters 375: 169-173. 1995
		Anderson (September 1995) Scientific Am. 124-126 and 128.
		Verma et al (1997) Nature 389, 239-242.
		Science News Report (1995) Science 269, 1050-1055.
		Li, et al., Adenovirus-mediated Bax Overexpression for the Induction of Therapeutic Apoptosis in Prostate Cancer, 2001, Cancer Research 61: 186-191.
		Miagkova et al. (1998) Proceed. Natl. Acad. Sci. 95, 13859-13864.
		Nita et al. (1996) Arthritis Rheum. 39, 820-828.
		Bandara et al., "Gene transfer to Synoviocytes: Prospects for Gene Treatment of Arthritis," <i>DNA and Cell Biology</i> , 1992, Vol. 11, No. 3, pp. 227-231.
		Roessler et al., "Adenoviral-mediated Gene Transfer to Rabbit Synovium In Vivo," <i>Journal of Clinical Investigation</i> , August, 1993, Vol. 92, pp. 1085-1092.
		Firestein et al., "Apoptosis in Rheumatoid Arthritis Synovium," <i>Arthritis and Rheumatism</i> , Abstracts of Scientific Presentations, September 1994, Vol. 37, No. 9 (Supplement), p. S311, Abstract 899.
		Fries, J.F. et al., "Nonsteroidal Anti-Inflammatory Drug-Associated Gastropathy Incidence and Risk Factor Models," <i>American Journal of Medicine</i> , Abstract, Vol. 91, No. 3, 1991, pgs. 213-222.

EXAMINER GT6536670.1 328342-220	DATE CONSIDERED
--	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1160-4	Application No.: 10/716,647
	Applicants: Firestein et al.	Confirmation No.: 7684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 18, 2003	Group Art Unit: 1633

	Makoto, Asamoto et al., "Mutations and Expression of the p53 Gene In Rat Bladder Carcinomas and Cell Lines," <i>Molecular Carcinogenesis</i> , Abstract, Vol. 9, No. 4, 1994, pgs. 236-244.
	Mountz, John D. et al., "Autoimmune Disease: A Problem of Defective Apoptosis," <i>Arthritis & Rheumatism</i> , Vol. 37, No. 10, October 1994, pgs. 1415-1420.
	Reme, Thierry et al., "Exon 6 Mutations of the p53 Tumor Suppressor Gene In Erosive Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , Abstract, Vol. 38, No. 9 Suppl., 1995, page S188.
	Wiman, K.G. et al., "Mutant P53 Detected In a Majority of Burkitt Lymphoma Cell Lines By Monoclonal Antibody PAB240," <i>Oncogene</i> , Abstract, Vol. 6, No. 9, 1991, pgs. 1633-1640.
	Evans and Robbins, 1996, "Pathways to gene therapy in rheumatoid arthritis," <i>Curr. Opin. Rheumatol.</i> 8(3):230-4.
	Makarov et al., 1996, "Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA," <i>Proc. Nat'l. Acad. Sci.</i> 93(1):402-6.
	Chernajovsky et al., 1995, "Inhibition of transfer of collagen-induced arthritis into SCID mice by <i>ex vivo</i> infection of spleen cells with retroviruses expressing soluble tumor necrosis factor receptor," <i>Gene Ther.</i> 2(10):731-5.
	Hanania et al., 1995, "Recent Advanced in the Application of Gene Therapy to Human Disease," <i>Am. J. Med.</i> 99(5):537-552.
	Evans and Robbins, 1995, "Progress toward the treatment of Arthritis by Gene Therapy," <i>Ann. Med.</i> 27(5):543-546.
	Zang et al., 1997, "Amelioration of Collagen-induced Arthritis by CD95 (Apo-1/Fas)-Ligand Gene Transfer," <i>J. Clin. Invest.</i> 100(8):1951-1957.
	Markarov et al., <i>Gene Ther</i> (Aug 1995), 2(6):424-428.
	Nita et al., <i>Arthritis Rheum</i> (May 1996), 39(5):820-828.
	Ghivizzani et al., <i>Gene Ther</i> (Sep 1997), 4(9):977-982

EXAMINER GT6536670.1 328342-220	DATE CONSIDERED
--	------------------------


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: UCSD1160-4	Application No.: 10/716,647
	Applicants: Firestein et al.	Confirmation No.: 7684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 18, 2003	Group Art Unit: 1633

		Nguyen et al., J. Rheumatol (Jun 1998), 25(6):1118-1125.
		Bandara et al., Proc Natl Acad Sci USA (Nov 1993), 90(22):10764-10768
		Hung et al., Gene Ther (Jan 1994), 1(1):64-69
		Evans et al., Hum Gene Ther (Jun 1996), 7(10):1261-1280
		Muller-Ladner et al., (Apr 1997), 158(7):2492-2498
		Bakker et al., Arthritis Rhem (May 1997), 40(5):893-900
		Chernajovsky et al., Gene Ther (June 1997), 4(6):553-559
		Le et al., Arthritis Rheum (Sep 1997), 40(9):1662-1669
		Bessis et al., Clin Exp Immunol (Feb 1998), 111(2):39-396
		Okamoto et al., Gene Ther (Mar 1998), 5(3):331-338
		Ghivizzani et al., Proc Natl Acad Sci USA (Apr 1998), 95(8):4613-4618
		Parks et al., J Immunol (May 1998), 160(9):4615-4619
		Song et al., J Clin Invest (June 1998), 101(12):2615-2621
		Ma et al., J Immunol (Aug 1998), 161(3): 1516-1524
		Takayanagi et al., ACR 62nd National Meeting, Nov. 8-12, 1998
		Kohasaka et al., ACR 62nd National Meeting, Nov. 8-12, 1998
		Lubberts et al., ACR 62nd National Meeting, Nov. 8-12, 1998
		Pelletier et al., ACR 62nd National Meeting, Nov. 8-12, 1998

EXAMINER GT\6536670.1 328342-220	DATE CONSIDERED
---	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 	Docket No.: UCSD1160-4 Applicants: Gary S. Firestein et al.	Application No.: 10/716,647 Confirmation No.: 7684
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: November 18, 2003	Group Art Unit: 7684

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		US2007/006542/A1	3/22/07	Firestein et al.	424	93.21	9/15/06

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
----------------	--	-----------------	------	---------	-------	-----------	-------------

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AA	Roth et al., <i>In vivo</i> molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma", <i>Cancer Res.</i> 55 :1-6, 1995.

EXAMINER GT6536718.1 328342-220	DATE CONSIDERED
--	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.